Cancer trials: money is not only currency of success

Alan Maynard's article ('Looking Askance', 19 November), on the cost-effectiveness of cancer services, was disappointing in its narrowness of approach.

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here